Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $21,700.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $10.85, for a total value of $21,700.00. Following the sale, the president now owns 2,905,138 shares in the company, valued at $31,520,747.30. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total value of $21,640.00.

Gyre Therapeutics Stock Up 5.6 %

Shares of GYRE opened at $11.19 on Monday. The stock has a 50 day simple moving average of $11.17 and a two-hundred day simple moving average of $12.59. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $26.37.

Institutional Trading of Gyre Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GYRE. FMR LLC bought a new position in Gyre Therapeutics in the third quarter worth $47,000. Barclays PLC boosted its position in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. State Street Corp boosted its position in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Gyre Therapeutics during the second quarter valued at $123,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics during the second quarter valued at $166,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.